

European Respiratory Society Annual Congress 2012

Abstract Number: 2321

Publication Number: 3273

Abstract Group: 4.3. Pulmonary Circulation and Pulmonary Vascular Disease

Keyword 1: Idiopathic pulmonary fibrosis **Keyword 2:** Pulmonary hypertension **Keyword 3:** Circulation

Title: Hemodynamics and response to therapy of pulmonary hypertension in patients with interstitial lung disease: Preliminary results of the "HYPID" prospective study

Prof. Vincent 16292 Cottin vincent.cottin@chu-lyon.fr MD ¹, Prof. Martine 16321 Reynaud-Gaubert martine.reynaud@ap-hm.fr MD ², Dr. Julie 16322 Traclet julie.traclet@chu-lyon.fr MD ¹, Dr. David 16323 Montani davidmontani@gmail.com MD ³, Prof. Hilario 16324 Nunes hilario.nunes@avc.aphp.fr MD ⁴, Prof. Benoit 16373 Wallaert benoit.wallaert@chru-lille.fr MD ⁵, Dr. Boubou 16391 Camara BCamara@chu-grenoble.fr MD ⁶, Dr. Chahera 16398 Khouatra chahera.khouatra@chu-lyon.fr MD ¹, Prof. David 16399 Launay launayd@gmail.com MD ⁷, Dr. Sylvain 16406 Marchand-Adam s.marchandadam@univ-tours.fr MD ⁸, Prof. Dominique 16407 Israel-Biet dominique.israel-biet@egp.aphp.fr MD ⁹, Dr. Romain 16408 Magnier magnier-r@chu-caen.fr MD ¹⁰, Dr. Laurent 16410 Tétu tetu.l@chu-toulouse.fr MD ¹¹, Ms. Sabrina 16411 Zeghmar sabrina.zeghmar@chu-lyon.fr ¹, Dr. Lize 16412 Kiakouama kiaslili@yahoo.fr MD ¹, Prof. Marc 16421 Humbert marc.humbert@abc.aphp.fr MD ³ and Prof. Jean-François 16459 Cordier jean-francois.cordier@chu-lyon.fr MD ¹. ¹ Respiratory Medicine, Hospices Civils de Lyon, Lyon, France ; ² Respiratory Medicine, AP-HM, Marseille, France ; ³ Respiratory Medicine, AP-HP, Clamart, France ; ⁴ Respiratory Medicine, AP-HP, Bobigny, France ; ⁵ Respiratory Medicine, CHRU, Lille, France ; ⁶ Respiratory Medicine, CHU, Grenoble, France ; ⁷ Internal Medicine, CHRU, Lille, France ; ⁸ Respiratory Medicine, CHU, Tours, France ; ⁹ Respiratory Medicine, AP-HP HEGP, Paris, France ; ¹⁰ Respiratory Medicine, CHU, Caen, France and ¹¹ Cardiology, CHU, Toulouse, France .

Body: Background. Pulmonary hypertension (PH) is associated with a shorter survival in patients with interstitial lung disease (ILD). Objective. To study the characteristics and response to specific PH therapy in patients with ILD and precapillary PH at right heart catheterization. Methods. A prospective multicenter observational study was conducted in French expert centers for rare pulmonary diseases or PH (NCT01443598). Results. The first 100 patients were studied (mean age 64 ± 10 years; 63 males). ILD was idiopathic pulmonary fibrosis (n=25), combined pulmonary fibrosis and emphysema syndrome (n=21), systemic sclerosis with ILD (n=26), sarcoidosis (n=8) and other ILD (n=20). Overall, NYHA class was I-II in 24% of patients and III-IV in 76%. Six-min walk distance was 289 ± 140 m. Hemodynamic characteristics were mPAP 38 ± 9.8 mmHg, CI 2.7 ± 0.65 L/min/m², and PVR 515 ± 243 dyn.s.cm-5. mPAP was >35 mmHg ("disproportionate" PH) in 56% of the cases. No correlation was found between pulmonary function and hemodynamic parameters. No differences were found between the 4 etiological groups for hemodynamic parameters. 36 patients with mPAP >35 mmHg received PH therapy and were evaluated at 3-6 months; mPAP decreased from 46 to 38 mmHg (p<0.0001), CI improved from 2.6 to 2.9 L/min/m² (p<0.05), and PVR decreased from 640 to 460 dyn.s.cm-5 (p<0.0001), but no difference was observed in 6

min walk distance or NYHA class. Conclusion. Hemodynamic characteristics do not correlate with pulmonary function and are comparable between etiological categories of ILD with PH. Preliminary data suggest that PH therapy may improve hemodynamics.